ヒト腫瘍細胞及び異種マウスにおけるマクロピノサイトシスにより媒介されるATP内在化のための蛍光顕微鏡

Executive Industry Relevance

This method enables direct visualization of extracellular ATP internalization via macropinocytosis in tumor models, providing mechanistic insight into nutrient scavenging pathways linked to cancer cell survival and metabolic adaptation. By quantifying ATP uptake in both in vitro and in vivo systems, the approach supports target validation efforts focused on purinergic signaling and endocytic flux as potential therapeutic vulnerabilities. The protocol’s adaptability across cell lines and xenograft models enhances its utility in preclinical de-risking strategies for oncology drug discovery.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of macropinocytosis-mediated ATP internalization as a functional readout for target engagement in nutrient uptake pathways.
• Operational Value: Provides a quantitative imaging-based assay to assess compound effects on ATP internalization and colocalization with endocytic tracers.
• Predictive Value: Supports mechanistic de-risking by linking extracellular nutrient scavenging to tumor cell fitness and resistance phenotypes.

Screening & Assay Development

• Assay Readiness: Uses nonhydrolyzable fluorescent ATP and dextran tracers to standardize detection of macropinocytosis-specific internalization events.
• Quantitative Output: Enables object count-based analysis of internalized ATP-positive cells via fluorescence microscopy for hit validation in screening campaigns.
• Scalability: Compatible with multi-channel imaging and automated image analysis for reproducible data generation across biological replicates.

Translational & Preclinical Research

• Disease Relevance: Models intratumoral ATP internalization in human tumor xenografts, reflecting the elevated extracellular ATP microenvironment observed in solid tumors.
• Translational Continuity: Bridges in vitro mechanistic findings with in vivo tumor tissue analysis to support target-to-pipeline alignment.
• Risk-Adjusted Advancement: Informs go/no-go decisions by revealing whether test compounds modulate ATP uptake in physiologically relevant tumor contexts.

Pipeline & Workflow Integration

The method fits within the discovery biology phase, where it supports hypothesis testing around nutrient acquisition mechanisms and pathway clarification in cancer metabolism, particularly for targets involved in macropinocytosis and purinergic signaling.

• Discovery Biology: Facilitates mechanistic interrogation of ATP internalization as a surrogate for macropinocytic activity and metabolic reprogramming in tumor cells.
• Screening: Generates quantitative imaging data to compare ATP internalization across treatment conditions, enabling assay standardization and hit confirmation.
• Analytics: Delivers colocalization and object count metrics that allow teams to quantify internalization efficiency and compare genetic or pharmacological perturbations.
• Translational Research: Extends findings from cell lines to xenograft tumors, supporting preclinical validation of target modulation in intact tissue.
• Enterprise Reuse: Establishes a reusable imaging platform for studying extracellular nutrient uptake across cancer models and metabolic disease systems.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in target validation by directly visualizing a key nutrient internalization pathway implicated in tumor aggressiveness.
• Operational Value: Standardizes ATP internalization assessment through reproducible sample preparation, imaging, and analysis workflows.
• Strategic Value: Reduces late-stage biological risk by enabling early evaluation of compounds targeting metabolic adaptation in cancer cells.
• Portfolio Impact: Supports risk-adjusted prioritization of targets involved in extracellular ATP scavenging and macropinocytic flux.

Implementation Considerations

• Requires expertise in fluorescence microscopy, tumor xenograft handling, and fluorescent tracer preparation.
• Depends on access to confocal or epifluorescence imaging systems with multi-channel acquisition capabilities.
• Necessitates standardization of tumor injection volumes, incubation times, and tissue processing across replicates.
• Involves optimization of ATP analog concentrations and dextran tracer ratios to avoid saturation or nonspecific signal.
• Limited by the need for terminal tissue collection, precluding longitudinal tracking in the same animal.

Biopharma FAQs